Rxivist logo

Pre-clinical studies of a recombinant adenoviral mucosal vaccine to prevent SARS-CoV-2 infection

By Anne C Moore, Emery G. Dora, Nadine Peinovich, Kiersten P. Tucker, Karen Lin, Mario Cortese, Sean N. Tucker

Posted 06 Sep 2020
bioRxiv DOI: 10.1101/2020.09.04.283853

There is an urgent need to develop efficacious vaccines against SARS-CoV-2 that also address the issues of deployment, equitable access, and vaccine acceptance. Ideally, the vaccine would prevent virus infection and transmission as well as preventing COVID-19 disease. We previously developed an oral adenovirus-based vaccine technology that induces both mucosal and systemic immunity in humans. Here we investigate the immunogenicity of a range of candidate adenovirusbased vaccines, expressing full or partial sequences of the spike and nucleocapsid proteins, in mice. We demonstrate that, compared to expression of the S1 domain or a stabilized spike antigen, the full length, wild-type spike antigen induces significantly higher neutralizing antibodies in the periphery and in the lungs, when the vaccine is administered mucosally. Antigen-specific CD4+ and CD8+ T cells were induced by this leading vaccine candidate at low and high doses. This fulllength spike antigen plus nucleocapsid adenovirus construct has been prioritized for further clinical development. ### Competing Interest Statement EGD, ND, KPT, KLM MC and SNT are current employees and/or own stock options in Vaxart, the sponsor of the studies. EGD and SNT are named as inventors covering a SARS-CoV-2 (nCoV-19) vaccine. SNT is named as an inventor on patents covering the vaccine platform. ACM declares no competing interest.

Download data

  • Downloaded 3,741 times
  • Download rankings, all-time:
    • Site-wide: 3,461
    • In immunology: 119
  • Year to date:
    • Site-wide: 2,647
  • Since beginning of last month:
    • Site-wide: 5,639

Altmetric data

Downloads over time

Distribution of downloads per paper, site-wide